The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

Cancer models developed with 3D bioprinting technology allow for rapid evaluation of individual drug responses.

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

6 The Carney triad, caused by mutation of the SDH gene, is a rare, nonhereditary condition characterized by the presence of 3 different types of tumors: GISTs, pulmonary chondromas ... chronic pain, ...

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...